# Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

> **NCT03624517** · PHASE4 · TERMINATED · sponsor: **Medical University of South Carolina** · enrollment: 34 (actual)

## Conditions studied

- Esophageal Varices
- Liver Cirrhoses
- Bleeding Esophageal Varices
- Upper Gastrointestinal Bleeding

## Interventions

- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT03624517
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-19
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Recruitment was severely affected due to COVID, so study was stopped prematurely.
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624517, "Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03624517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*